Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ZTS by emailGet an email when ZTS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ZTS, unsubscribe in one click. Privacy
📣 What ZTS Says Is Next
this year · “Zoetis expects to launch Lenivia and Portela in Canada and the EU this year.”
Company press release, Feb 12, 2026 · SEC filing
fourth quarter · “Expects to Deliver 3% to 5% Organic Operational Growth in Revenue PARSIPPANY, N.J. - February 12, 2026 - Zoetis Inc. (NYSE: ZTS), the world's leading animal health company, today reported its financial results for the fourth quarter and full year 2025 and provided full year guidance for 2026.”
Company press release, Feb 12, 2026 · SEC filing
in 2026 · “Zoetis expects to launch Lenivia in Canada in 2026.”
Company press release, Nov 4, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full ZTS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ZTS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.